163 related articles for article (PubMed ID: 34302528)
1. Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression.
Gundlach JP; Hauser C; Schlegel FM; Willms A; Halske C; Röder C; Krüger S; Röcken C; Becker T; Kalthoff H; Trauzold A
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3313-3324. PubMed ID: 34302528
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.
Gundlach JP; Hauser C; Schlegel FM; Böger C; Röder C; Röcken C; Becker T; Egberts JH; Kalthoff H; Trauzold A
BMC Cancer; 2018 Jul; 18(1):777. PubMed ID: 30064384
[TBL] [Abstract][Full Text] [Related]
3. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma.
Hristov AC; Cope L; Reyes MD; Singh M; Iacobuzio-Donahue C; Maitra A; Resar LM
Mod Pathol; 2009 Jan; 22(1):43-9. PubMed ID: 18843278
[TBL] [Abstract][Full Text] [Related]
4. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
[TBL] [Abstract][Full Text] [Related]
5. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma.
Piscuoglio S; Zlobec I; Pallante P; Sepe R; Esposito F; Zimmermann A; Diamantis I; Terracciano L; Fusco A; Karamitopoulou E
Histopathology; 2012 Feb; 60(3):397-404. PubMed ID: 22276603
[TBL] [Abstract][Full Text] [Related]
6. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue.
Abe N; Watanabe T; Suzuki Y; Matsumoto N; Masaki T; Mori T; Sugiyama M; Chiappetta G; Fusco A; Atomi Y
Br J Cancer; 2003 Dec; 89(11):2104-9. PubMed ID: 14647145
[TBL] [Abstract][Full Text] [Related]
7. MiR-497 inhibits cell proliferation and invasion ability by targeting HMGA2 in pancreatic ductal adenocarcinoma.
Zhou ZG; Xu C; Dong Z; Wang YP; Duan JY; Yan CQ
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):122-129. PubMed ID: 31957824
[TBL] [Abstract][Full Text] [Related]
8. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC.
Strell C; Norberg KJ; Mezheyeuski A; Schnittert J; Kuninty PR; Moro CF; Paulsson J; Schultz NA; Calatayud D; Löhr JM; Frings O; Verbeke CS; Heuchel RL; Prakash J; Johansen JS; Östman A
Br J Cancer; 2017 Jun; 117(1):65-77. PubMed ID: 28524160
[TBL] [Abstract][Full Text] [Related]
9. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.
Chiou SH; Dorsch M; Kusch E; Naranjo S; Kozak MM; Koong AC; Winslow MM; Grüner BM
Sci Rep; 2018 Sep; 8(1):14008. PubMed ID: 30228296
[TBL] [Abstract][Full Text] [Related]
10. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
11. High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients.
Liu Z; Wu K; Yang Z; Wu A
Mol Cell Biochem; 2015 Nov; 409(1-2):155-62. PubMed ID: 26183485
[TBL] [Abstract][Full Text] [Related]
12. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma.
Li K; Yang J; Chen J; Shi Y; Zhang Z; Chen W
Oncol Lett; 2020 Feb; 19(2):1584-1592. PubMed ID: 31966084
[TBL] [Abstract][Full Text] [Related]
13. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
14. MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2.
Wang YD; Mao JD; Wang JF; Xu MQ
Technol Cancer Res Treat; 2020; 19():1533033820928143. PubMed ID: 32588766
[TBL] [Abstract][Full Text] [Related]
15. A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.
Paladino D; Yue P; Furuya H; Acoba J; Rosser CJ; Turkson J
Oncotarget; 2016 Feb; 7(6):7253-67. PubMed ID: 26695438
[TBL] [Abstract][Full Text] [Related]
16. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
17. Association of subcellular localization of TEAD transcription factors with outcome and progression in pancreatic ductal adenocarcinoma.
Drexler R; Fahy R; Küchler M; Wagner KC; Reese T; Ehmke M; Feyerabend B; Kleine M; Oldhafer KJ
Pancreatology; 2021 Jan; 21(1):170-179. PubMed ID: 33317954
[TBL] [Abstract][Full Text] [Related]
18. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.
Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J
Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
20. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma.
Sperveslage J; Frank S; Heneweer C; Egberts J; Schniewind B; Buchholz M; Bergmann F; Giese N; Munding J; Hahn SA; Kalthoff H; Klöppel G; Sipos B
Int J Cancer; 2012 Aug; 131(4):E371-81. PubMed ID: 22020953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
